Navigation Links
Cynosure Files Patent Infringement Lawsuit Against CoolTouch Inc.
Date:1/9/2008

Company and Largest Shareholder El.En. S.p.A. Seek Injunction and Monetary

Damages

WESTFORD, Mass., Jan. 9 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, and its largest shareholder, El.En. S.p.A., today filed a patent infringement lawsuit against CoolTouch Inc. in U.S. District Court for the District of Massachusetts. The lawsuit alleges that CoolTouch's 1320 nm CoolLipo(TM) laser system infringes on U.S. Patent No. 6,206,873 (the 873 patent), which covers technology using laser energy to remove subcutaneous fat. Cynosure is the exclusive licensee of the 873 patent, which is owned by El.En.

The 873 patent is a fundamental component of the Smartlipo(TM) LaserBodyScuplting(SM) Workstation, a groundbreaking system designed as an alternative to traditional liposuction in patients with small areas of localized fat. Cynosure received U.S. Food and Drug Administration clearance to market the Smartlipo workstation in the fourth quarter of 2006. The product, which was launched in early 2007, uses a 1064 nm Nd:YAG laser to deliver energy directly to subcutaneous fat cells, causing them to rupture. The emitted fat-melting energy also coagulates tissue, thus inducing collagen retraction and tissue tightening.

The lawsuit filed by Cynosure and El.En. seeks monetary damages and an injunction against CoolTouch to prohibit further infringement.

"Smartlipo has become the gold standard for the minimally invasive removal of localized fat, and we will vigorously defend our intellectual property position," said Cynosure President and Chief Executive Officer Michael Davin. "As evidenced by the new higher-powered 10- and 18-watt workstations we introduced in 2007, we continue to make significant investments in the future of the Smartlipo workstation. We believe that CoolTouch's device infringes on the 873 patent, and we initiated this litigation to protect our rights and represent the best interest of our shareholders."

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.

For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosure.com.

Safe Harbor

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the company's expectations and future financial performance, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.


'/>"/>
SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cynosure to Present at the Maxim Group Growth Conference
2. Cynosure to Announce Third-Quarter 2007 Financial Results on November 1
3. Alvarado Hospital Files Countersuit Against Blue Shield
4. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
5. Pharsight Files Application for Nasdaq Capital Market Listing
6. Gentiva(R) Health Services Files Universal Shelf Registration Statement
7. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
8. CIGNA Behavioral Health Offers Members Online Provider Profiles
9. American Media Operations, Inc. Files Form 10-Q For First Quarter 2007
10. RxElite Files Registration Statement with Securities and Exchange Commission
11. Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology: